Impact of genetic variation in OATP transporters to drug disposition and response

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 1, 2013, Pages 4-18

  Gong, Inna Y ^a   Kim, Richard B ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Adverse drug events; Drug disposition; Drug efficacy; Drug response; Drug transporters; OATPs; Personalized medicine; Pharmacogenetics; Pharmacogenomics; Pharmacokinetics

Indexed keywords

ATORVASTATIN; BQ 123A; CERIVASTATIN; COSITECAN; DELTORPHIN; DOCETAXEL; ENALAPRIL; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; EZETIMIBE; FEXOFENADINE; FIRTECAN; FLUINDOSTATIN; IRINOTECAN; LOPINAVIR; METHOTREXATE; MEVINOLIN; MONTELUKAST; MYCOPHENOLIC ACID; NATEGLINIDE; OLMESARTAN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER POLYPEPTIDE; PACLITAXEL; PITAVASTATIN; PRAVASTATIN; REPAGLINIDE; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; TALINOLOL; TORASEMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG UPTAKE; ENZYME SPECIFICITY; GASTROINTESTINAL TOXICITY; GENE; GENE DOSAGE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HETEROZYGOTE; HUMAN; LEUKOPENIA; LIVER CELL; LIVER INJURY; LIVER TOXICITY; LOSS OF FUNCTION MUTATION; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NEUTROPENIA; PROTEIN EXPRESSION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1A2 GENE; SLCO1B1 GENE; SLCO1B3 GENE;

EID: 84874606257     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RV-099     Document Type: Review

References (145)

1. Lazarou, J., Pomeranz, B. H. and Corey, P. N.: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 279: 1200-1205 (1998).
2. Severino, G. and Del Zompo, M.: Adverse drug reactions: role of pharmacogenomics. Pharmacol Res., 49: 363-73 (2004).
3. Scott, S. A.: Personalizing medicine with clinical pharmacogenetics. Genet. Med., 13: 987-995 (2011).
4. Spear, B. B., Heath-Chiozzi, M. and Huff, J.: Clinical application of pharmacogenetics. Trends Mol. Med., 7: 201-204 (2001).
5. Meyer, U. A.: Pharmacogenetics - Five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet, 5: 669-676 (2004).
6. Wei, C. Y, Lee, M. T. and Chen, Y. T.: Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum. Mol. Genet (2012).
7. Wilkinson, G. R.: Drug metabolism and variability among patients in drug response. N. Engl J. Med., 352: 2211-2221 (2005).
8. DeGorter, M. K., Xia, C. Q., Yang, J. J. and Kim, R. B.: Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol Toxicol, 52: 249-273 (2012).
9. Ho, R. H. and Kim, R. B.: Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol Ther, 78: 260-277 (2005).
10. Lee, N. H: Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents. Anticancer Agents Med. Chem., 10: 583-592 (2010).
11. Giacomini, K. M., Huang, S. M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L., Chu, X., Dahlin, A., Evers, R, Fischer, V., Hillgren, K. M., Hoffmaster, K. A., Ishikawa, T., Keppler, D., Kim, R. B., Lee, C. A., Niemi, M., Polli, J. W., Sugiyama, Y, Swaan, P. W., Ware, J. A., Wright, S. H, Yee, S. W., Zamek-Gliszczynski, M. J. and Zhang, L.: Membrane transporters in drug development. Nat. Rev. Drug Discov, 9: 215-236 (2010).
12. Hagenbuch, B. and Meier, P. J.: The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Ada, 1609: 1-18 (2003).
13. Konig, J., Cui, Y, Nies, A. T and Keppler, D.: A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol Gastrointest Liver Physiol, 278: G156-G164 (2000).
14. Kullak-Ublick, G A., Ismair, M. G, Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P. J. and Hagenbuch, B.: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, 120: 525-533 (2001).
15. Tamai, I., Nezu, J., Uchino, H, Sai, Y, Oku, A., Shimane, M. and Tsuji, A.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun., 273: 251-260 (2000).
16. Kullak-Ublick, G. A., Hagenbuch, B., Stieger, B., Schteingart, C. D., Hofmann, A. F., Wolkoff A. W. and Meier, P. J.: Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology, 109: 1274-1282 (1995).
17. Niemi, M.: Role of OATP transporters in the disposition of drugs. Pharmacogenomics, 8: 787-802 (2007).
18. Kalliokoski, A. and Niemi, M.: Impact of OATP transporters on pharmacokinetics. Br J. Pharmacol, 158: 693-705 (2009).
19. Abe, T., Kakyo, M., Tokui, T, Nakagomi, R., Nishio, T, Nakai, D., Nomura, H, Unno, M., Suzuki, M., Naitoh, T., Matsuno, S. and Yawo, H.: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol Chem., 274: 17159-17163 (1999).
20. Tirana, R. G., Leake, B. F., Merino, G and Kim, R. B.: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol Chem., 276: 35669-35675 (2001).
21. Kameyama, Y, Yamashita, K., Kobayashi, K., Hosokawa, M. and Chiba, K.: Functional characterization of SLCOIBI (OATP-C) variants, SLC01B1*5, SLC01B1*15 and SLCOlBl*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmaco-genet. Genomics, 15: 513-522 (2005).
22. Michalski, C, Cui, Y, Nies, A. T., Nuessler, A. K., Neuhaus, P., Zanger, U. M., Klein, K., Eichelbaum, M., Keppler, D. and Konig, J.: A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol Chem., 277: 43058-43063 (2002).
23. Ho, R. H., Tirana, R. G, Leake, B. F., Glaeser, H., Lee, W., Lemke, C. J., Wang, Y and Kim, R. B.: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology, 130: 1793-1806 (2006).
24. Oswald, S., Konig, J., Lutjohann, D., Giessmann, T., Kroemer, H. K., Rimmbach, C, Rosskopf D., Framm, M. F. and Siegmund, W.: Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP IB 1. Pharmacogenet. Genomics, 18: 559-568 (2008).
25. Nozawa, T., Minami, H., Sugiura, S., Tsuji, A. and Tamai, I.: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos., 33: 434-39 (2005).
26. Tirana, R. G., Leake, B. R, Wolkoff, A. W. and Kim, R. B.: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifamp in-mediated pregnane X receptor activation. J. Pharmacol. Exp. Then, 304: 223-228 (2003).
27. Katz, D. A., Carr, R., Grimm, D. R., Xiong, H., Holley-Shanks, R., Mueller, T., Leake, B., Wang, Q., Han, L., Wang, P. G., Edeki, T., Sahelijo, L., Doan, T., Allen, A., Spear, B. B. and Kim, R. B.: Organic anion transporting polypeptide 1B1 activity classified by SLCOIBI genotype influences atrasentan pharmacokinetics. Clin. Pharmacol. Then, 79: 186-196 (2006).
28. Nozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J., Sai, Y., Tsuji, A. and Yokoi, T.: Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther, 302: 804-813 (2002).
29. Iwai, M., Suzuki, H., Ieiri, I., Otsubo, K. and Sugiyama, Y: Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics, 14: 749-757 (2004).
30. Niemi, M., Schaeffeler, E., Lang, T., Framm, M. F., Neuvonen, M., Kyrklund, C, Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., Eichelbaum, M. and Kivisto, K. T.: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCOIBI). Pharmacogenetics, 14: 429-40 (2004).
31. Furihata, T., Satoh, N., Ohishi, T., Ugajin, M., Kameyama, Y, Morimoto, K., Matsumoto, S., Yamashita, K., Kobayashi, K. and Chiba, K.: Functional analysis of a mutation in the SLCOIBI gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy. Pharmacogenomics J., 9: 185-193 (2009).
32. Neuvonen, P. J., Kantola, T. and Kivisto, K. T.: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther, 63: 332-341 (1998).
33. Hsiang, B., Zhu, Y, Wang, Z., Wu, Y, Sasseville, V., Yang, W. P. and Kirchgessner, T. G.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem., 274: 37161-37168 (1999).
34. Nishizato, Y, Ieiri, I., Suzuki, H., Kimura, M., Kawabata, K., Hirota, T., Takane, H., Irie, S., Kusuhara, H., Urasaki, Y, Urae, A., Higuchi, S., Otsubo, K. and Sugiyama, Y: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther, 73: 554-565 (2003).
35. Igel, M., Arnold, K. A., Niemi, M., Hofmann, U., Schwab, M., Lutjohann, D., von Bergmann, K., Eichelbaum, M. and Kivisto, K. T.: Impact of the SLCOIBI polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin. Pharmacol. Ther, 79: 419-26 (2006).
36. Pasanen, M. K., Fredrikson, H., Neuvonen, P. J. and Niemi, M.: Different effects of SLCOIBI polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther, 82: 726-733 (2007).
37. Lee, E., Ryan, S., Birmingham, B., Zalikowski, J., March, R., Ambrose, H., Moore, R., Lee, C, Chen, Y and Schneck, D.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther, 78: 330-341 (2005).
38. Pasanen, M. K., Neuvonen, M., Neuvonen, P. J. and Niemi, M.: SLCOIBI polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics, 16: 873-879 (2006).
39. Mwinyi, J., Johne, A., Bauer, S., Roots, I. and Gerloff, T.: Evidence for inverse effects of OATP-C (SLC21A6) 5 and lb haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther, 75: 415-21 (2004).
40. Maeda, K., Ieiri, I., Yasuda, K., Fujino, A., Fujiwara, H., Otsubo, K., Hirano, M., Watanabe, T., Kitamura, Y, Kusuhara, H. and Sugiyama, Y: Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther, 79: 427-39 (2006).
41. Choi, J. H., Lee, M. G., Cho, J. Y, Lee, J. E., Kim, K. H. and Park, K.: Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther, 83: 251-257 (2008).
42. Hedman, M., Antikainen, M., Holmberg, C, Neuvonen, M., Eichelbaum, M., Kivisto, K. T., Neuvonen, P. J. and Niemi, M.: Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCOIBI and ABCB1 genes. Br J. Clin. Pharmacol, 61: 706-715 (2006).
43. Niemi, M., Neuvonen, P. J., Hofmann, U., Backman, J. T., Schwab, M., Lutjohann, D., von Bergmann, K., Eichelbaum, M. and Kivisto, K. T.: Acute effects of pravastatin on cholesterol synthesis are associated with SLCOIBI (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics, 15: 303-309 (2005).
44. Gerloff, T., Schaefer, M., Mwinyi, J., Johne, A., Sudhop, T., Lutjohann, D., Roots, I. and von Bergmann, K.: Influence of the SLCOIBI* lb and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. Naunyn Schmiedebergs Arch. Pharmacol, 373: 45-50 (2006).
45. Tachibana-Iimori, R., Tabara, Y, Kusuhara, H., Kohara, K., Kawamoto, R., Nakura, J., Tokunaga, K., Kondo, I., Sugiyama, Y and Miki, T.: Effect of genetic polymorphism of OATP-C (SLCOIBI) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet, 19: 375-380 (2004).
46. Generaux, G. T., Bonomo, F. M., Johnson, M. and Doan, K. M.: Impact of SLCOIBI (OATP IB 1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica, 41: 639-651 (2011).
47. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, L, Lathrop, M. and Collins, R.: SLCOIBI variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med., 359: 789-799 (2008).
48. Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B.A. and Ginsburg, G. S.: The SLC01B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol, 54: 1609-1616 (2009).
49. Donnelly, L. A., Doney, A. S., Tavendale, R., Lang, C. C, Pearson, E. R., Colhoun, H. M., McCarthy, M. I., Hattersley, A. T., Morris, A. D. and Palmer, C. N.: Common nonsynonymous substitutions in SLCOIBI predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin. Pharmacol Ther, 89: 210-216 (2011).
50. Brunham, L. R., Lansberg, P. J., Zhang, L., Miao, F., Carter, C, Hovingh, G. K., Visscher, H., Jukema, J. W, Stalenhoef, A. F., Ross, C. J., Carleton, B. C, Kastelein, J. J. and Hayden, M. R.: Differential effect of the rs4149056 variant in SLCOIBI on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J., 12: 233-237 (2012).
51. Niemi, M., Pasanen, M. K. and Neuvonen, P. J.: Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev., 63: 157-181 (2011).
52. Niemi, M., Backman, J. T., Kajosaari, L. I., Leathart, J. B., Neuvonen, M., Daly, A. K., Eichelbaum, M., Kivisto, K. T. and Neuvonen, P. J.: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther, 77: 468-78 (2005).
53. Kalliokoski, A., Neuvonen, M., Neuvonen, P. J. and Niemi, M.: The effect of SLCOIBI polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br. J. Clin. Pharmacol, 66: 818-825 (2008).
54. Kalliokoski, A., Backman, J. T., Neuvonen, P. J. and Niemi, M.: Effects of the SLCOIBI* IB haplotype on the pharmacokinetics andpharmaco-dynamics of repaglinide and nateglinide. Pharmacogenet. Genomics, 18: 937-942 (2008).
55. Kalliokoski, A., Neuvonen, M., Neuvonen, P. J. and Niemi, M.: Different effects of SLCOIBI polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J. Clin. Pharmacol, 48: 311-321 (2008).
56. Zhang, W., He, Y J., Han, C. T., Liu, Z. Q., Li, Q., Fan, L., Tan, Z. R., Zhang, W X., Yu, B. N., Wang, D., Hu, D. L. and Zhou, H. H.: Effect of SLCOIBI genetic polymorphism on the pharmacokinetics of nateglinide. Br. J. Clin. Pharmacol, 62: 567-572 (2006).
57. Aquilante, C. L., Bushman, L. R., Knutsen, S. D., Burt, L. E., Rome, L. C. and Kosmiski, L. A.: Influence of SLCOIBI and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum. Genomics, 3: 7-16 (2008).
58. Trevino, L. R., Shimasaki, N., Yang, W, Panetta, J. C, Cheng, C, Pei, D., Chan, D., Sparreboom, A., Giacomini, K. M., Pui, C. H., Evans, W. E. and Relling, M. V.: Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol, 27: 5972-5978 (2009).
59. Li, L. M., Chen, L., Deng, G. H., Tan, W. T., Dan, Y J., Wang, R. Q. and Chen, W. S.: SLCOIBI *15 haplotype is associated with rifampin-induced liver injury. Mol Med. Rep., 6: 75-82 (2012).
60. Picard, N., Yee, S. W., Woillard, J. B., Lebranchu, Y, Le Meur, Y, Giacomini, K. M. and Marquet, P.: The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin. Pharmacol. Then, 87: 100-108(2010).
61. Geng, R, Jiao, Z., Dao, Y I, Qiu, X. Y, Ding, J. J., Shi, X. J., Li, Z. D. and Zhong, M. K.: The association of the UGT1A8, SLC01B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals. Clin. Chim. Ada, 413: 683-690 (2012).
62. Michelon, H., Konig, J., Durrbach, A., Quteineh, L., Verstuyft, C, Furlan, V., Ferlicot, S., Letierce, A., Charpentier, B., Fromm, M. F. and Becquemont, L.: SLCOIBI genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenom-ics, 11: 1703-1713 (2010).
63. Niemi, M., Kivisto, K. T., Hofmann, U., Schwab, M., Eichelbaum, M. and Fromm, M. F.: Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCOIBI gene (encoding OATP1B1). Br J. Clin. Pharmacol, 59: 602-604 (2005).
64. Han, J. Y, Lim, H. S., Shin, E. S., Yoo, Y K., Park, Y H., Lee, J. E., Kim, H. T. and Lee, J. S.: Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmaco-kinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer, 59: 69-75 (2008).
65. Hartkoorn, R. C, Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., Sora, E. S., James, C. E., Gibbons, S., Bray, P. G., Back, D. J., Khoo, S. H. and Owen, A.: HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCOIBI polymorphisms. Pharmacogenet. Genomics, 20: 112-120(2010).
66. Suwannakul, S., Ieiri, I., Kimura, M., Kawabata, K., Kusuhara, H., Hirota, T., Irie, S., Sugiyama, Y and Higuchi, S.: Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCOIBI polymorphism. J. Hum. Genet, 53: 899-904 (2008).
67. Vormfelde, S. V., Toliat, M. R., Schirmer, M., Meineke, I., Nurnberg, P. and Brockmoller, J.: The polymorphisms Asnl30Asp and Vall74Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther, 83: 815-817 (2008).
68. Tian, L., Liu, H., Xie, S., Jiang, J., Han, L., Huang, Y and Li, Y: Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single-and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin. Ther, 33: 655-663 (2011).
69. Iida, A., Saito, S., Sekine, A., Mishima, C, Kondo, K., Kitamura, Y, Harigae, S., Osawa, S. and Nakamura, Y: Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH: ubiquinone oxidoreductase flavoproteins. J. Hum. Genet., 46: 668-683 (2001).
70. Letschert, K., Keppler, D. and Konig, J.: Mutations in the SLC01B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics, 14: 441-52 (2004).
71. Smith, N. F., Acharya, M. R., Desai, N., Figg, W. D. and Sparreboom, A.: Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol. Ther, 4: 815-818 (2005).
72. Chae, Y J., Lee, K. R., Noh, C. K., Chong, S., Kim, D. D., Shim, C. K. and Chung, S. J.: Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population. J. Pharm. Sci., 101: 1302-1313 (2012).
73. Hamada, A., Sissung, T., Price, D. K., Danesi, R., Chau, C. H., Sharifi N., Venzon, D., Maeda, K., Nagao, K., Sparreboom, A., Mitsuya, H., Dahut, W. L. and Figg, W. D.: Effect of SLC01B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer. Clin. Cancer Res., 14: 3312-3318(2008).
74. Schwarz, U. I., Meyer zu Schwabedissen, H. E., Tirana, R. G., Suzuki, A., Leake, B. F., Mokrab, Y, Mizuguchi, K., Ho, R. H. and Kim, R. B.: Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet. Genomics, 21: 103-114 (2011).
75. Smith, N. F., Marsh, S., Scott-Horton, T. J., Hamada, A., Mielke, S., Mross, K., Figg, W. D., Verweij, J., McLeod, H. L. and Sparreboom, A.: Variants in the SLC01B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther, 81: 76-82 (2007).
76. Chew, S. C, Singh, O., Chen, X., Ramasamy, R. D., Kulkarni, T., Lee, E. J., Tan, E. H., Lim, W. T. and Chowbay, B.: The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLC01B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol, 67: 1471-1478 (2011).
77. Baker, S. D., Verweij, J., Cusatis, G. A., van Schaik, R. H., Marsh, S., Orwick, S. J., Franke, R. M., Hu, S., Schuetz, E. G., Lamba, V, Messersmith, W. A., Wolff, A. C, Carducci, M. A. and Sparreboom, A.: Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther, 85: 155-163 (2009).
78. Kiyotani, K., Mushiroda, T., Kubo, M., Zembutsu, H., Sugiyama, Y and Nakamura, Y: Association of genetic polymorphisms in SLC01B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci., 99: 967-972 (2008).
79. Yamada, A., Maeda, K., Ishiguro, N., Tsuda, Y, Igarashi, T., Ebner, T., Roth, W., Ikushiro, S. and Sugiyama, Y: The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet. Genomics, 21: 523-530 (2011).
80. Endo, S., Fukahori, A., Tokuhiro, S., Shinagawa, A., Walker, J., Yoshihara, K., Ishizuka, H., Ieiri, I. and Sugiyama, Y: Association study of genetic polymorphisms of drug transporters, SLCOIBI, SLC01B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure. J. Hum. Genet., 57: 531-544 (2012).
81. Miura, M., Satoh, S., Inoue, K., Kagaya, H., Saito, M., Inoue, T., Suzuki, T. and Habuchi, T.: Influence of SLCOIBI, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J. Clin. Pharmacol., 63: 1161-1169 (2007).
82. Yamakawa, Y, Hamada, A., Nakashima, R., Yuki, M., Hirayama, C, Kawaguchi, T. and Saito, H.: Association of genetic polymorphisms in the influx transporter SLC01B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther. DrugMonit, 33: 244-250 (2011).
83. Konig, J., Cui, Y, Nies, A. T. and Keppler, D.: Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem., 275: 23161-23168 (2000).
84. Nozawa, T., Imai, K., Nezu, J., Tsuji, A. and Tamai, I.: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther, 308: 438-45 (2004).
85. Imanaga, J., Kotegawa, T., Imai, H., Tsutsumi, K., Yoshizato, T., Ohyama, T., Shirasaka, Y, Tamai, I., Tateishi, T. and Ohashi, K.: The effects of the SLC02B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet. Genomics, 21: 84-93 (2011).
86. Ieiri, I., Doi, Y, Maeda, K., Sasaki, T., Kimura, M., Hirota, T., Chiyoda, T., Miyagawa, M., Irie, S., Iwasaki, K. and Sugiyama, Y: Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLC02B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J. Clin. Pharmacol, 52: 1078-1089 (2012).
87. Akamine, Y, Miura, M., Sunagawa, S., Kagaya, H., Yasui-Furukori, N. and Uno, T.: Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers. Xenobiotica, 40: 782-789 (2010).
88. Mougey, E. B., Feng, H., Castro, M., Irvin, C. G. and Lima, J. J.: Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet. Genomics, 19: 129-138 (2009).
89. Rebello, S., Zhao, S., Hariry, S., Dahlke, M., Alexander, N., Vapurcuyan, A., Hanna, I. and Jarugula, V: Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. Eur. J. Clin. Pharmacol, 68: 697-708 (2012).
90. Knauer, M. J., Urquhart, B. L., Meyer zu Schwabedissen, H. E., Schwarz, U. I., Lemke, C. J., Leake, B. F., Kim, R. B. and Tirana, R. G.: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ. Res., 106: 297-306 (2010).
91. Franke, R. M., Scherkenbach, L. A. and Sparreboom, A.: Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmaco-genomics, 10: 339-344 (2009).
92. Meier, Y, Eloranta, J. J., Darimont, J., Ismair, M. G., Hiller, C, Fried, M., Kullak-Ublick, G. A. and Vavricka, S. R.: Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab. Dispos., 35: 590-594 (2007).
93. Gao, B., Hagenbuch, B., Kullak-Ublick, G. A., Benke, D., Aguzzi, A. and Meier, P. J.: Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J. Pharmacol. Exp. Then, 294: 73-79 (2000).
94. Lee, W., Glaeser, H., Smith, L. H., Roberts, R. L., Moeckel, G. W., Gervasini, G., Leake, B. F. and Kim, R. B.: Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem., 280: 9610-9617 (2005).
95. Badagnani, I., Castro, R. A., Taylor, T. R., Brett, C. M., Huang, C. C, Stryke, D., Kawamoto, M., Johns, S. J., Ferrin, T. E., Carlson, E. J., Burchard, E. G. and Giacomini, K. M.: Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther, 318: 521-529 (2006).
96. Eechoute, K., Franke, R. M., Loos, W. J., Scherkenbach, L. A., Boere, L, Verweij, J., Gurney, H., Kim, R. B., Tirana, R. G., Mathijssen, R. H. and Sparreboom, A.: Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin. Pharmacol. Ther, 89: 816-820 (2011).
97. Yamakawa, Y., Hamada, A., Shuto, T., Yuki, M., Uchida, T., Kai, H., Kawaguchi, T. and Saito, H.: Pharmacokinetic impact of SLC01A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia. Clin. Pharmacol. Ther, 90: 157-163 (2011).
98. Angelini, S., Soverini, S., Ravegnini, G., Barnett, M., Turrini, E., Thornquist, M., Pane, F., Hughes, T. P., White, D. L., Radich, J., Kim, D. W., Saglio, G., Cilloni, D., Iacobucci, I., Perini, G., Woodman, R., Cantelli-Forti, G., Baccarani, M., Hrelia, P. and Martinelli, G.: Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica (2012).
99. Svoboda, M., Riha, J., Wlcek, K., Jaeger, W and Thalhammer, T.: Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr Drug Metab., 12: 139-153 (2011).
100. Nakakariya, M., Shimada, T., Irokawa, M., Maeda, T. and Tamai, I.: Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. Drug Metab. Pharmaco-kinet, 23: 347-355 (2008).
101. Oostendorp, R. L., van de Steeg, E., van der Kruijssen, C. M., Beijnen, J. H., Kenworthy, K. E., Schinkel, A. H. and Schellens, J. H.: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) Bl and/or ABCG2 inhibitors. Drug Metab. Dispos., 37: 917-923 (2009).
102. Ni, W, Ji, J., Dai, Z., Papp, A., Johnson, A. J., Ahn, S., Farley, K. L., Lin, T. S., Dalton, J. T., Li, X., Jarjoura, D., Byrd, J. C, Sadee, W., Grever, M. R. and Phelps, M. A.: Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCOIBI/OATPIBI in flavopiridol disposition. PLoS ONE, 5: el3792 (2010).
103. Nozawa, T., Sugiura, S., Nakajima, M., Goto, A., Yokoi, T., Nezu, J., Tsuji, A. and Tamai, I.: Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab. Dispos., 32: 291-294(2004).
104. Matsushima, S., Maeda, K., Hayashi, H., Debori, Y, Schinkel, A. H., Schuetz, J. D., Kusuhara, H. and Sugiyama, Y: Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mot Pharmacol, 73: 1474-1483 (2008).
105. Treiber, A., Schneiter, R., Hausler, S. and Stieger, B.: Bosentan is a substrate of human OATP IB 1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Dispos., 35: 1400-1407 (2007).
106. Liu, L., Cui, Y, Chung, A. Y, Shitara, Y, Sugiyama, Y, Keppler, D. and Pang, K. S.: Vectorial transport of enalapril by Oatplal/Mrp2 and OATP IB 1 and OATP1B3/MRP2 in rat and human livers. J. Pharmacol Exp. Ther, 318: 395-02 (2006).
107. Nakagomi-Hagihara, R., Nakai, D., Kawai, K., Yoshigae, Y, Tokui, T., Abe, T. and Ikeda, T.: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab. Dispos., 34: 862-869 (2006).
108. Yamashiro, W., Maeda, K., Hirouchi, M., Adachi, Y, Hu, Z. and Sugiyama, Y: Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II ATI-receptor, in humans. Drug Metab. Dispos., 34: 1247-1254 (2006).
109. Werner, U., Werner, D., Heinbuchner, S., Graf, B., Ince, H., Kische, S., Thurmann, P., Konig, J., Framm, M. F. and Zolk, O.: Gender is an important determinant of the disposition of the loop diuretic torasemide. J. Clin. Pharmacol, 50: 160-168 (2010).
110. Sandhu, P., Lee, W., Xu, X., Leake, B. F., Yamazaki, M., Stone, J. A., Lin, J. H., Pearson, P. G. and Kim, R. B.: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab. Dispos., 33: 676-682 (2005).
111. Shitara, Y, Hirano, M., Sato, H. and Sugiyama, Y: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATPlBl:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther, 311: 228-236 (2004).
112. Kopplow, K., Letschert, K., Konig, J., Walter, B. and Keppler, D.: Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol, 68: 1031-1038 (2005).
113. Neuvonen, P. J., Niemi, M. and Backman, J. T.: Drug interactions with lip id-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther, 80: 565-581 (2006).
114. Hirano, M., Maeda, K., Shitara, Y and Sugiyama, Y: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther, 311: 139-146 (2004).
115. Deng, J. W., Song, I. S., Shin, H. J., Yeo, C. W., Cho, D. Y, Shon, J. H. and Shin, J. G.: The effect of SLC01B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLC01B1*15. Pharmacogenet. Genomics, 18: 424-33 (2008).
116. Simonson, S. G., Raza, A., Martin, P. D., Mitchell, P. D., Jarcho, J. A., Brown, C. D., Windass, A. S. and Schneck, D. W: Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther, 76: 167-177 (2004).
117. Vavricka, S. R., Van Montfoort, J., Ha, H. R., Meier, P. J. and Fattinger, K.: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology, 36: 164-172 (2002).
118. Hu, S., Franke, R. M., Filipski, K. K., Hu, C, Orwick, S. J., de Bruijn, E. A., Burger, H., Baker, S. D. and Sparreboom, A.: Interaction of imatinib with human organic ion carriers. Clin. Cancer Res., 14: 3141-3148 (2008).
119. Abe, T., Unno, M., Onogawa, T. and Tokui, T.: [Molecular identification of organic anion transporter oatp/LST family]. Tanpakushitsu Kakusan Koso, 46: 612-620 (2001).
120. Yamaguchi, H., Kobayashi, M., Okada, M., Takeuchi, T., Unno, M., Abe, T., Goto, J., Hishinuma, T. and Mano, N.: Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett., 260: 163-169 (2008).
121. Shimizu, M., Fuse, K., Okudaira, K., Nishigaki, R., Maeda, K., Kusuhara, H. and Sugiyama, Y: Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos., 33: 1477-1481 (2005).
122. Ishiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., Roth, W, Igarashi, T. and Sugiyama, Y: Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab. Dispos., 34: 1109-1115 (2006).
123. Seithel, A., Eberl, S., Singer, K., Auge, D., Heinkele, G., Wolf, N. B., Dorje, F., Framm, M. F. and Konig, J.: The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos., 35: 779-786 (2007).
124. Tamai, I., Nozawa, T., Koshida, M., Nezu, J., Sai, Y and Tsuji, A.: Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm. Res., 18: 1262-1269 (2001).
125. Grube, M., Kock, K., Oswald, S., Draber, K., Meissner, K., Eckel, L., Bohm, M., Felix, S. B., Vogelgesang, S., Jedlitschky, G., Siegmund, W, Warzok, R. and Kroemer, H. K.: Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther, 80: 607-620 (2006).
126. van Montfoort, J. E., Stieger, B., Meijer, D. K., Weinmann, H. J., Meier, P. J. and Fattinger, K. E.: Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatpl. J. Pharmacol. Exp. Ther, 290: 153-157 (1999).
127. Franke, R. M., Baker, S. D., Mathijssen, R. H., Schuetz, E. G. and Sparreboom, A.: Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin. Pharmacol. Ther, 84: 704-709 (2008).
128. Kullak-Ublick, G. A., Glasa, J., Boker, C, Oswald, M., Grutzner, U., Hagenbuch, B., Stieger, B., Meier, P. J., Beuers, U., Kramer, W., Wess, G. and Paumgartner, G.: Chlorambucil-taurocholate is transported by ile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology, 113: 1295-1305 (1997).
129. Bossuyt, X., Muller, M. and Meier, P. J.: Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J. Hepatol, 25: 733-738 (1996).
130. Su, Y., Zhang, X. and Sinko, P. J.: Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm., 1: 49-56 (2004).
131. Fujino, H., Saito, T., Ogawa, S. and Kojima, J.: Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J. Pharm. Pharmacol, 57: 1305-1311 (2005).
132. Elens, L., Capron, A., Kerckhove, V. V., Lerut, J., Mourad, M., Lison, D., Wallemacq, P. and Haufraid, V.: 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet. Genomics, 17: 873-883 (2007).
133. Bernsdorf, A., Giessmann, T., Modess, C, Wegner, D., Igelbrink, S., Hecker, U., Haenisch, S., Cascorbi, I., Terhaag, B. and Siegmund, W.: Simvastatin does not influence die intestinal P-glycoprotein and MPR2, and die disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCOIBI polymorphisms. Br J. Clin. Pharmacol, 61: 440-50 (2006).
134. Lee, Y J., Lee, M. G., Lim, L. A., Jang, S. B. and Chung, J. Y: Effects of SLCOIBI and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int. J. Clin. Pharmacol. Ther, 48: 36-45 (2010).
135. Niemi, M., Pasanen, M. K. and Neuvonen, P. J.: SLCOIBI polymorphism and sex affect die pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther, 80: 356-366 (2006).
136. Ho, R. H., Choi, L., Lee, W., Mayo, G., Schwarz, U. I., Tirana, R. G., Bailey, D. G., Michael Stein, C. and Kim, R. B.: Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet. Genomics, 17: 647-656 (2007).
137. Zhang, W., Chen, B. L., Ozdemir, V., He, Y J., Zhou, G., Peng, D. D., Deng, S., Xie, Q. Y, Xie, W., Xu, L. Y, Wang, L. C, Fan, L., Wang, A. and Zhou, H. H.: SLCOIBI 521T--C functional genetic polymorphism and lip id-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br. J. Clin. Pharmacol, 64: 346-352 (2007).
138. Kalliokoski, A., Neuvonen, M., Neuvonen, P. J. and Niemi, M.: No significant effect of SLCOIBI polymorphism on die pharmacokinetics of rosiglitazone and pioglitazone. Br. J. Clin. Pharmacol, 65: 78-86 (2008).
139. Xiang, X., Jada, S. R., Li, H. H., Fan, L., Tham, L. S., Wong, C. I., Lee, S. C, Lim, R., Zhou, Q. Y, Goh, B. C, Tan, E. H. and Chowbay, B.: Pharmacogenetics of SLCOIBI gene and the impact of *lb and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet. Genomics, 16: 683-691 (2006).
140. Chung, J. Y, Cho, J. Y, Yu, K. S., Kim, J. R., Oh, D. S., Jung, H. R., Lim, K. S., Moon, K. H., Shin, S. G. and Jang, I. J.: Effect of OATP1B1 (SLCOIBI) variant alleles on die pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther, 78: 342-350 (2005).
141. Ieiri, I., Suwannakul, S., Maeda, K., Uchimaru, H., Hashimoto, K., Kimura, M., Fujino, H., Hirano, M., Kusuhara, H., Irie, S., Higuchi, S. and Sugiyama, Y: SLCOIBI (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther, 82: 541-547 (2007).
142. Choi, C. L, Lee, Y J., Lee, H. I., Kim, B. H., Kim, M. J., Jang, C. G., Bae, J. W. and Lee, S. Y: Effects of the SLC01B1*15 allele on the pharmacokinetics of pitavastatin. Xenobiotica, 42: 496-501 (2012).
143. Takane, H., Miyata, M., Burioka, N., Shigemasa, C, Shimizu, E., Otsubo, K. and Ieiri, I.: Pharmacogenetic determinants of variability in lip id-lowering response to pravastatin therapy. J. Hum. Genet, 51: 822-826 (2006).
144. Couvert, P., Giral, P., Dejager, S., Gu, J., Huby, T., Chapman, M. J., Bruckert, E. and Carrie, A.: Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics, 9: 1217-1227 (2008).
145. Morimoto, K., Oishi, T., Ueda, S., Ueda, M., Hosokawa, M. and Chiba, K.: A novel variant allele of OATP-C (SLCOIBI) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab. Pharmaco-kinet, 19: 453-55 (2004)